Exchange: NASDAQ·Updated 07:38 PM EDT

TEM News

News
all
press releases
Ambry Genetics Announces GenomeNext, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of GenomeNext and GenomeReveal, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases...
Business Wire
Ambry Genetics Announces GenomeNext, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of GenomeNext and GenomeReveal, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases...
Business Wire
More News
Tempus AI Expands Strategic Collaborations to Drive Future Growth
TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.
Zacks
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
TEM's strong data licensing growth, AI-driven innovations and rising shares favor holding the stock, but premium valuation and reimbursement risks warrant caution.
Zacks
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.read more...
Benzinga
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA (pembrolizumab...
Business Wire
Here's How Tempus AI is Capitalizing on AI-ECG Market Growth
TEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.
Zacks
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireAUSTIN, Texas, Oct. 1, 2026Equity Insider News CommentaryAUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ --Towards Healthcare projects that the global AI...
PR Newswire
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 2327 in Madrid. At this years congress, Tempus will showcase clinical research revealing insights in cancer...
Business Wire
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral...
Business Wire
Tempus AI Chief Accounting Officer Sells $529,650 of Stock
Key PointsThe transaction involved 7,062 shares with an estimated value of $529,650 as of the transaction date...
Nasdaq News: Markets

Advertisement|Remove ads.